Editorial

• Volume 11 Number 1/2 January/February 2010

Conference reports

• 12th European AIDS Society Conference (EACS) 11-14 November 2009, Cologne

• Screening for anal cancer recommended for HIV-positive men

• Once-daily darunavir/r monotherapy is suboptimal as initial regimen in treatment-naïve people

• Central fat accumulation remains a significant problem in patients starting HAART after 2005 with higher incidence in women compared to men

• Alendronate improves bone mineral density in HIV-positive people with osteoporosis at 96 weeks

• TMC278 did not show teratogenic potential in animal models

• Etravirine pregnancy data from five cases: no dose adjustment required

• No clinically relevant interactions between TMC278 and oral contraceptives (norethindrone plus ethinylestradiol)

• Gender-based differences in patients receiving antiretroviral therapy

• Pilot PK study of two generic paediatric formulations of lopinavir/ritonavir vs originator products

• Other selected PK and drug interaction summaries from EACS

• 11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV (IWADR) 26-28 October 2009, Philadelphia

• The HCV pipeline – efficacy and side effect of compounds in Phase 3 studies

Antiretrovirals

• GSK issues Dear Doctor letter in the US: fosamprenavir and cardiovascular risk

Guidelines

• US guideline update: treat when CD4 is less than 500 cells/mm3

• WHO publish major revisions to HIV management guidelines

• Updated paediatric HIV treatment guidelines (PENTA, 2009)

Side effects

• HIV disease and renal function

PMTCT and maternal health

• Pregnancy not nevirapine associated with risk of hepatotoxicity in large cohort comparison

• Birth defects following efavirenz exposure in a South African Hospital

Cancer and HIV

• Outcomes from screening study for anal cancer in HIV-positive compared to HIV-negative patients

PK and drug interactions

• No interaction between tipranavir/ritonavir and efavirenz

• Significant interactions between tipranavir/ritonavir and statins

• Summary of interactions between vivriviroc and other ARVs

• Significant interaction between atazanavir/ritonavir and the antipsychotic drug quetiapine

Treatment access

• FDA approval of generic ARVs

• UNITAID decision to fund ‘patent pool’ to boost access to new medicines

• PEPFAR launches five-year strategy

• Global Fund approves US$2.4 billion in new grants

Basic science and immunology

• Early predictors of disease progression

• Bridging the neurology-immunology barrier

• Free journal on immunology and cardiovascular disease

Transmission and prevention

• Male circumcision: new data supporting protective mechanism

• A caution for male circumcision programmes: high complication rates highlighted outside a trial setting

Vaccines and microbicides

• PRO 2000 microbicide gel does not pan out

On the web

• Reports and journals

• Community resources and publications

• Conference reports and online abstracts

PDFs

• Volume 11 Number 1/2 January/February 2010 PDF